<DOC>
	<DOCNO>NCT02365974</DOCNO>
	<brief_summary>Uncontrolled blood pressure represent main factor development target organ lesion , consequently , cardiovascular event , lead cause morbidity mortality worldwide . In case resistant hypertension precede target organ lesion , strongly influence risk factor associate disease . To control disease require adequate intense therapeutic approach include lifestyle change use several antihypertensive drug . However , result always satisfactory despite intensive treatment . Of different pathophysiological mechanism involve pathogenesis resistant hypertension ( RH ) , two , sympathetic overstimulation therapy block sympathetic system , widely study . But , approach invasive expensive . Another possible approach transcutaneous electrical nerve stimulation ( TENS ) , non-invasive method modulates activity inhibit primary afferent pathway use low-frequency transcutaneous electrical stimulation . Some study show TENS reduces blood pressure patient hypertension . The current study evaluate effect apply TENS cervicothoracic region subject resistant hypertension , seek develop new low cost readily available therapy treat group hypertensive individual .</brief_summary>
	<brief_title>Transcutaneous Electrical Nerve Stimulation ( TENS ) Arterial Stiffness Blood Pressure</brief_title>
	<detailed_description>Patients divide two group : treatment control ( sham group ) . The sham group submit procedure fit stimulation equipment . However , patient submit stimulation . Both group undergo physical examination start end study period determine anthropometric variable . The BMI , define weight ( kg ) divide patient 's height square ( m2 ) , calculate . The height determine centimeter use measure tape individual barefoot . Individuals BMI &lt; 25 kg/m² classify normal , overweight BMI 25 30 kg/m² , obese BMI ≥30 kg/m² . The waist circumference measure use measure tape half distance iliac crest lower costal margin . Patients undergo follow test end four-week study period : 24-hour ambulatory blood pressure monitoring ( ABPM ) , 24-hour dynamic electrocardiography , continuous measurement beat-to-beat BP , endothelial function measurement radial artery applanation tonometry ( AT ) . Biochemical test perform two time point , four-week study period include blood sugar , total cholesterol ( TC ) , high-density lipoprotein cholesterol ( HDL-C ) , triglyceride ( TG ) , creatinine , potassium , uric acid , plasma insulin level . Blood sugar , TC , HDL-C TG level determine colorimetry fast 12 hour use dimension device Dade Behring reagent . Diagnosis diabetes mellitus ( DM ) establish patient history , use hypoglycemic drug measurement serum glucose . The LDL-C fraction calculate use formula LDL-C = TC - HDL-C - TG / 5 ( TG &lt; 400 mg/dL ) . Additionally , electrochemiluminescence method use measure plasma insulin ( immunoassay vitro quantitative determination human insulin serum plasma use Elecsys 1010/2010 immunoassay E170 modular analytics analyzer Roche ) . The homeostasis model assessment insulin resistance ( HOMA-IR ) index apply obtain blood sugar insulin level order determine insulin resistance functional capability pancreatic beta cell . Insulin resistance characterize ratio exceeds 2.71 . The HOMA-IR index calculate use follow formula : HOMA-IR : Fasting insulin ( McU/mL ) x fast glucose ( mmol/L* ) 22.5 In order convert glucose concentration mmol/L necessary multiply value mg/dL 0.0555 . Measurement serum creatinine perform standardized enzyme-kinetic biochemical test consider high serum creatinine &gt; 1.4 mg/dL . Urinary sodium potassium level ( mEq/L ) evaluate flame photometry . Urinary sodium excretion calculate multiply urinary sodium potassium concentration mEq/L 24-hour urine volume . The 24-hour urine volume urinary creatinine concentration assess calculate creatinine clearance adjust body surface . Specific biochemical test consider : serum aldosterone ( AS ) , plasma renin activity ( PRA ) , high-sensitivity C-reactive protein ( hsCRP ) , metalloproteinase 9 ( MMP-9 ) , tissue inhibitor metalloproteinases ( TIMP-1 TIMP-2 ) , nitrites nitrate , interleukin-1 , 6 , 8 , 10 18 ( IL-1 , IL-6 , IL-8 , IL-10 IL-18 ) , tumor necrosis factor ( TNF-α ) , thromboxane B2 ( TXB2 ) , fibrinogen , intercellular adhesion molecule ( ICAM-1 ) , plasminogen activator inhibitor ( PAI-1 ) , angiotensin convert enzyme ( ACE ) angiotensin II ( Ang II ) .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Autonomic Nervous System Diseases</mesh_term>
	<mesh_term>Primary Dysautonomias</mesh_term>
	<criteria>RH patient take least three antihypertensive drug full dos , one preferably thiazide diuretic ; Age 40 70 year . Use cardiac pacemaker Cardiac electrical conduction abnormality evidence ECG stress test ( ergometry ) Dermatological abnormality site application TENS Uncontrolled diabetes patient use oral hypoglycemic agent insulin glycated Hb ≥ 7.5 % Secondary Hypertension Patients adhere lifestyle change recommend physician lowsodium diet weight loss Moderate severe cervicalthoracic scoliosis Obesity body mass index ( BMI ) ≥35 kg/m2</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>arterial stiffness</keyword>
	<keyword>resistant hypertension</keyword>
	<keyword>sympathetic system</keyword>
	<keyword>blood pressure</keyword>
	<keyword>transcutaneous electrical nerve stimulation</keyword>
</DOC>